DLB — Dolby Laboratories Income Statement
0.000.00%
Last trade - 00:00
- $7.47bn
- $6.69bn
- $1.30bn
- 96
- 27
- 77
- 74
2019 September 27th | 2020 September 25th | 2021 September 24th | 2022 September 30th | 2023 September 29th | |
---|---|---|---|---|---|
Period Length: | 52 W | 52 W | 52 W | 53 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,242 | 1,162 | 1,281 | 1,254 | 1,300 |
Cost of Revenue | |||||
Gross Profit | 1,081 | 1,015 | 1,151 | 1,112 | 1,147 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 985 | 943 | 937 | 1,047 | 1,084 |
Operating Profit | 257 | 219 | 344 | 207 | 216 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 282 | 240 | 355 | 215 | 250 |
Provision for Income Taxes | |||||
Net Income After Taxes | 358 | 232 | 318 | 184 | 202 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 255 | 231 | 310 | 184 | 201 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 255 | 231 | 310 | 184 | 201 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.64 | 2.26 | 2.93 | 1.89 | 2.44 |
Dividends per Share |